Advertisement
BSX vs MMSI
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Merit Medical Systems (MMSI) Stock Comparison
Key Takeaways
- Divergent momentum: BSX has underperformed recently amid a cyberattack and device recalls, while MMSI has rallied on accelerating growth and raised guidance.
- Scale contrast: Boston Scientific is a diversified large-cap medical technology leader, whereas Merit Medical is a mid-cap maker of disposable interventional and therapeutic devices.
- Earnings trajectory: Merit Medical recently beat estimates and raised its 2026 outlook; Boston Scientific trimmed its full-year guidance following operational disruptions.
- Valuation profile: BSX trades at a lower forward earnings multiple than its industry, while MMSI carries a premium to its sub-industry after its recent advance.
- Risk mix differs: BSX faces near-term recall and competitive headwinds; MMSI contends with tariffs, pricing pressure, and smaller scale.
Introduction
Boston Scientific Corporation (BSX) and Merit Medical Systems, Inc. (MMSI) both operate in the medical device space, yet they represent very different points on the risk-and-scale spectrum. Boston Scientific is a global, diversified healthcare technology giant, while Merit Medical is a focused mid-cap supplier of single-use devices for interventional and therapeutic procedures. Comparing these two names helps investors weigh a large-cap turnaround story against a smaller company riding renewed growth momentum. Traders focused on relative performance, market positioning, and sector exposure may find this stock comparison useful for understanding how sentiment and fundamentals are diverging within medical technology.
BSX Overview and Recent Performance
Boston Scientific is a global medical technology leader spanning cardiovascular, respiratory, digestive, oncological, neurological, and urological devices. In recent weeks, the company's shares have been pressured by an August cybersecurity incident that disrupted manufacturing and shipping, along with a series of voluntary device recalls, including its LUX-Dx insertable cardiac monitors. These setbacks weighed on sentiment and prompted management to lower full-year revenue growth guidance, while several analysts trimmed price targets.
The company's underlying operations remain substantial. In its most recent reported quarter, revenue topped $5 billion with double-digit growth, supported by strong neuromodulation and endoscopy results, though urology growth has lagged. The stock has underperformed the broader market and the medical sector over recent months, trading below prior highs despite a consensus analyst rating that still skews toward "Buy." The near-term narrative centers on restoring shipping capacity and rebuilding confidence in key franchises such as Watchman and electrophysiology.
MMSI Overview and Recent Performance
Merit Medical Systems designs, manufactures, and markets proprietary disposable medical devices used in minimally invasive cardiology, radiology, oncology, critical care, and endoscopy procedures. In recent weeks, the stock has gained notably, reflecting a stronger operating trajectory. Its latest quarterly results showed revenue growth of roughly 9.5% year over year, with adjusted earnings per share (EPS) rising 18% and beating consensus estimates by a wide margin.
Management subsequently raised its full-year revenue and adjusted EPS guidance, citing strength in therapeutic products such as Cardiac Therapies and Endoscopy, which grew well into the double digits. Margin expansion has also improved, though the company faces a meaningful tariff burden and foreign-exchange variability. With a market capitalization in the single-digit billions, Merit Medical is far smaller than Boston Scientific, and its forward earnings multiple has moved above its sub-industry average, reflecting the market's willingness to pay for improving growth.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across a wide range of strategies, timeframes, and risk profiles. Because not every bot fits every market environment, Tickeron curates only the strongest and most suitable performers into its Trending AI Robots section. These featured bots vary in trading style, holding period, win rate, and the basket of securities they monitor, allowing traders to review measurable statistics before selecting an approach that matches their objectives. Exploring this curated list can help investors identify AI-driven strategies aligned with current conditions. Visit the Trending AI Robots page to browse the latest top-performing bots.
Head-to-Head Comparison
The sharpest contrast between these two companies is scale and diversification. Boston Scientific generates tens of billions in annual revenue across multiple franchises and geographies, giving it broad product breadth but also exposing it to headline risk from recalls and competitive resets in core categories. Merit Medical's smaller, more focused portfolio allows faster shifts toward higher-growth therapeutic segments, but it lacks the same cushion against pricing and tariff pressures.
Momentum also points in opposite directions. Merit Medical has been in an earnings-upgrade cycle, with accelerating organic growth and improving margins supporting its recent rally. Boston Scientific, by contrast, has been navigating an estimate-reduction phase driven by the cyberattack and recall fallout. On valuation, BSX trades at a discount to its industry on a forward price-to-earnings basis, while MMSI now trades at a premium to its sub-industry. In terms of sector exposure, both are squarely medical technology, but BSX skews toward large, complex cardiovascular and surgical systems, whereas MMSI emphasizes higher-volume disposable and consumable devices.
Tickeron AI Verdict
Based on observable factors such as trend consistency, momentum, and the direction of estimate revisions, Tickeron's AI would likely favor MMSI in the current environment. The company has demonstrated stronger relative performance, an upward-trending earnings trajectory, and clearer near-term catalysts, all of which tend to register favorably in AI-driven trend and momentum models. BSX, by contrast, shows weaker near-term trend consistency amid ongoing operational disruptions and reduced guidance. That said, this is a probabilistic assessment rather than a definitive claim, and the AI's preference could shift if Boston Scientific stabilizes its operations or if Merit Medical's valuation premium limits further upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a StrongBuy and MMSI is a Hold.
BSX's RSI Indicator recovers from oversold territory
The RSI Indicator for BSX moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 15 of the 25 cases the stock moved higher. This puts the odds of a move higher at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on November 09, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 22 of 46 cases over the following month. The odds of a continued upward trend are 48%.
BSX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 200 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 51 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MMSI's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for MMSI moved out of overbought territory on October 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In 25 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMSI as a result. In 53 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
The Moving Average Convergence Divergence Histogram (MACD) for MMSI turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 21 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
MMSI moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 59 cases where MMSI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The 10-day moving average for MMSI crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.
Following a +3.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMSI advanced for three days, in 198 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
MMSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. MMSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.101) is normal, around the industry mean (4.964). P/E Ratio (35.604) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.574) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.273) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
BSX | MMSI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 96 | 77 | |
SMR RATING 1..100 | 55 | 74 | |
PRICE GROWTH RATING 1..100 | 62 | 46 | |
P/E GROWTH RATING 1..100 | 95 | 73 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSX's Valuation (66) in the Medical Specialties industry is in the same range as MMSI (73). This means that BSX’s stock grew similarly to MMSI’s over the last 12 months.
MMSI's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as BSX (96). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is in the same range as MMSI (74). This means that BSX’s stock grew similarly to MMSI’s over the last 12 months.
MMSI's Price Growth Rating (46) in the Medical Specialties industry is in the same range as BSX (62). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
MMSI's P/E Growth Rating (73) in the Medical Specialties industry is in the same range as BSX (95). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
| BSX | MMSI | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 60% | 2 days ago 66% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 48% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 57% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 58% |
| Advances ODDS (%) | 2 days ago 60% | 21 days ago 66% |
| Declines ODDS (%) | 6 days ago 54% | 6 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 67% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while MMSI’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- MMSI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while MMSI’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 5 bearish.
- MMSI’s TA Score: 4 bullish, 5 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +2.76% price change this week, while MMSI (@Pharmaceuticals: Other) price change was +4.34% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.
Reported Earning Dates
BSX is expected to report earnings on Feb 03, 2027.
MMSI is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+1.96% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +1.54% | ||
| ISRG - BSX | 71% Closely correlated | -2.28% | ||
| MMSI - BSX | 56% Loosely correlated | -0.69% | ||
| ALC - BSX | 49% Loosely correlated | -1.44% | ||
| MDT - BSX | 49% Loosely correlated | -1.17% | ||
| NTRA - BSX | 45% Loosely correlated | -2.62% | ||
More | ||||
MMSI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MMSI has been loosely correlated with BSX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MMSI jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To MMSI | 1D Price Change % | ||
|---|---|---|---|---|
| MMSI | 100% | -0.69% | ||
| BSX - MMSI | 56% Loosely correlated | +1.54% | ||
| SYK - MMSI | 50% Loosely correlated | -0.44% | ||
| ICUI - MMSI | 50% Loosely correlated | +1.82% | ||
| ISRG - MMSI | 48% Loosely correlated | -2.28% | ||
| COO - MMSI | 44% Loosely correlated | -0.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FLYU | 45.36 | N/A | N/A |
| MicroSectors Travel 3x Leveraged ETN (FLYU) | |||
| CALF | 57.68 | -0.05 | -0.09% |
| Pacer US Small Cap Cash Cows ETF (CALF) | |||
| EURL | 45.39 | -0.28 | -0.62% |
| Direxion Daily FTSE Europe Bull 3X ETF (EURL) | |||
| VKQ | 9.03 | -0.10 | -1.10% |
| Invesco Municipal Trust | |||
| EVG | 10.18 | -0.14 | -1.36% |
| Eaton Vance Short Duration Diversified Income Fund | |||